MarketPR
In focus for APUS: Apimeds Pharmaceuticals US, Inc. disclosed in a Form 8-K filed August 6, 2026 the appointment of Dr.
Christopher Kim as Chief Scientific Officer, effective August 5, putting him in charge of scientific, clinical, and regulatory development of the company's APITOX program.
The next confirmable milestone is a regulatory submission or clinical update tied to that program, now under Dr.
Kim carries what the filing describes as "extensive scientific, technical, and regulatory expertise" specific to APITOX, and the company states he has been closely associated with the program for many years.
Keep reading